EP4167969A4 - An orally disintegrating tablet formulation comprising sitagliptin - Google Patents

An orally disintegrating tablet formulation comprising sitagliptin

Info

Publication number
EP4167969A4
EP4167969A4 EP21830086.1A EP21830086A EP4167969A4 EP 4167969 A4 EP4167969 A4 EP 4167969A4 EP 21830086 A EP21830086 A EP 21830086A EP 4167969 A4 EP4167969 A4 EP 4167969A4
Authority
EP
European Patent Office
Prior art keywords
sitagliptin
tablet formulation
orally disintegrating
disintegrating tablet
orally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21830086.1A
Other languages
German (de)
French (fr)
Other versions
EP4167969A1 (en
Inventor
Seval Ataman
Bozyel Muge Ulusoy
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4167969A1 publication Critical patent/EP4167969A1/en
Publication of EP4167969A4 publication Critical patent/EP4167969A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21830086.1A 2020-06-23 2021-05-07 An orally disintegrating tablet formulation comprising sitagliptin Pending EP4167969A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/09724A TR202009724A2 (en) 2020-06-23 2020-06-23 FORMULATION OF CYTAGLIPTIN IN ORAL DISTRIBUTION TABLET
PCT/TR2021/050440 WO2021262114A1 (en) 2020-06-23 2021-05-07 An orally disintegrating tablet formulation comprising sitagliptin

Publications (2)

Publication Number Publication Date
EP4167969A1 EP4167969A1 (en) 2023-04-26
EP4167969A4 true EP4167969A4 (en) 2024-04-17

Family

ID=79281616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21830086.1A Pending EP4167969A4 (en) 2020-06-23 2021-05-07 An orally disintegrating tablet formulation comprising sitagliptin

Country Status (3)

Country Link
EP (1) EP4167969A4 (en)
TR (1) TR202009724A2 (en)
WO (1) WO2021262114A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012781A2 (en) * 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2011123641A1 (en) * 2010-03-31 2011-10-06 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201721700A2 (en) * 2017-12-26 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DISTRIBUTED FORMULATIONS OF SAXAGLIPT IN THE MOUTH

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012781A2 (en) * 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2011123641A1 (en) * 2010-03-31 2011-10-06 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABBARAJU LAKSHMI ET AL: "INTERNATIONAL RESEARCH JOURNAL OF PHARMACY FORMULATION AND EVALUATION OF TASTE MASKED ORALLY DISINTEGRATING TABLETS OF SITAGLIPTIN PHOSPHATE MONOHYDRATE", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 3, 1 January 2012 (2012-01-01), pages 305 - 308, XP055163565 *
NAGA SUBRAHMANYAM S ET AL: "Formulation And Evaluation Of Sitagliptin Oral Disintegration Tablets Using Synthetic Superdisintegrants", WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, IN, vol. 8, no. 1, 30 November 2017 (2017-11-30), pages 863 - 882, XP009533943, ISSN: 2277-7105, DOI: 10.20959/WJPR20191-13856 *
See also references of WO2021262114A1 *

Also Published As

Publication number Publication date
WO2021262114A1 (en) 2021-12-30
TR202009724A2 (en) 2022-01-21
EP4167969A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
EP3490539A4 (en) Novel orally administrable formulation
EP3996695A4 (en) Cannabidiol orally disintegrating tablets
IL262312A (en) Orally disintegrating tablets
EP3556345A4 (en) Orally disintegrated tablet comprising carbamate compound
EP3449912A4 (en) Orally disintegrating tablet
EP3616696A4 (en) Orally administrable enzalutamide-containing pharmaceutical composition
EP3328360A4 (en) Tofacitinib orally disintegrating tablets
EP3694522A4 (en) Bi-layer pharmaceutical tablet formulation
EP3784672A4 (en) Tablet formulations comprising metformin and sitagliptin
IL290894A (en) Pharmaceutical formulation
EP4167969A4 (en) An orally disintegrating tablet formulation comprising sitagliptin
GB202010230D0 (en) Pharmaceutical formulation
WO2010081722A3 (en) Orally disintegrating tablets for the treatment of pain
PT3446684T (en) Orally disintegrating tablet
EP3908275A4 (en) Rapidly disintegrating oral tablet
EP4048276A4 (en) Solid pharmaceutical formulations comprising ticagrelor
IL297081A (en) Pharmaceutical formulation
CA204145S (en) Chewable tablet
EP3733166A4 (en) Cyclic orally disintegrating tablet
IL286942A (en) Vaginal tablet formulation
GB201906473D0 (en) Pharmaceutical formulation
GB202319953D0 (en) Tablet formulations involving alvelestat
EP4059502A4 (en) Orally disintegrating tablet
EP4081218A4 (en) Orally dissolving formulations of prucalopride
CA200107S (en) Pharmaceutical tablet

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240315

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20240311BHEP

Ipc: A61K 31/444 20060101ALI20240311BHEP

Ipc: A61K 9/20 20060101AFI20240311BHEP